In yesterday’s Wall Street session, Akebia Therapeutics Inc. (NASDAQ:AKBA) shares traded at $0.87, down -3.25% from the previous session.
2 analysts cover Akebia Therapeutics Inc. (NASDAQ:AKBA), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $4.00 and a low of $2.00, we find $3.00. Given the previous closing price of $0.90, this indicates a potential upside of 233.33 percent. AKBA stock price is now -17.28% away from the 50-day moving average and 32.35% away from the 200-day moving average. The market capitalization of the company currently stands at $164.20M.
The stock has received a hold rating from 1 analysts and a buy rating from 1. Brokers who have rated the stock have averaged $3.00 as their price target over the next twelve months.
With the price target enhanced from $2 to $4, Piper Sandler Upgraded its rating from Neutral to Overweight for Akebia Therapeutics Inc. (NASDAQ: AKBA).
In other news, Dahan Michel, SVP, Chief Operating Officer sold 95,478 shares of the company’s stock on May 25. The stock was sold for $116,760 at an average price of $1.22. Upon completion of the transaction, the SVP, Chief Operating Officer now directly owns 574,037 shares in the company, valued at $0.5 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 25, SVP, Chief Legal Officer Hadas Nicole R. sold 63,186 shares of the business’s stock. A total of $77,270 was realized by selling the stock at an average price of $1.22. This leaves the insider owning 524,344 shares of the company worth $0.46 million. Insiders disposed of 504,069 shares of company stock worth roughly $0.44 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AKBA stock. A new stake in Akebia Therapeutics Inc. shares was purchased by WIPFLI FINANCIAL ADVISORS LLC, during the first quarter worth $175,000. HRT FINANCIAL LP invested $130,000 in shares of AKBA during the first quarter. In the first quarter, MIRABELLA FINANCIAL SERVICES LLP acquired a new stake in Akebia Therapeutics Inc. valued at approximately $123,000. VIRTU FINANCIAL LLC acquired a new stake in AKBA for approximately $85,000. LPL FINANCIAL LLC purchased a new stake in AKBA valued at around $25,000 in the second quarter. In total, there are 95 active investors with 29.20% ownership of the company’s stock.
On Wednesday morning Akebia Therapeutics Inc. (NASDAQ: AKBA) stock kicked off with the opening price of $0.9022. During the past 12 months, Akebia Therapeutics Inc. has had a low of $0.24 and a high of $1.63. The fifty day moving average price for AKBA is $1.0595 and a two-hundred day moving average price translates $0.6620 for the stock.
The latest earnings results from Akebia Therapeutics Inc. (NASDAQ: AKBA) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.14, beating analysts’ expectations of -$0.15 by 0.01. This compares to -$0.35 EPS in the same period last year. The net profit margin was -20.80% and return on equity was -316.90% for AKBA. The company reported revenue of $40.13 million for the quarter, compared to $61.7 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -34.96 percent. For the current quarter, analysts expect AKBA to generate $59.1M in revenue.
Akebia Therapeutics Inc.(AKBA) Company Profile
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
